PandemieGrippaleV1, France, Analysis, bibRecord, 000387

Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.

Identifieur interne : 000387 ( France/Analysis ); précédent : 000386; suivant : 000388

Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.

Auteurs : Julie Medina [France] ; Houda Boukhebza [France] ; Amélie De Saint Jean [France] ; Régis Sodoyer [France] ; Isabelle Legastelois [France] ; Catherine Moste [France]

Source :

Vaccine [ 1873-2518 ] ; 2015.

RBID : pubmed:26206270

Descripteurs français

English descriptors

KwdEn :
- Amino Acid Sequence, Animals, Antigens, Viral (genetics), Antigens, Viral (immunology), Chlorocebus aethiops, Dogs, Hemagglutinin Glycoproteins, Influenza Virus (chemistry), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (growth & development), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (chemistry), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Madin Darby Canine Kidney Cells, Molecular Sequence Data, Neuraminidase (genetics), Reassortant Viruses (genetics), Recombinant Fusion Proteins (chemistry), Recombinant Fusion Proteins (immunology), Reverse Genetics (methods), Sequence Alignment, Sequence Analysis, DNA, Vero Cells.
MESH :
- chemical , chemistry : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Recombinant Fusion Proteins.
- chemical , genetics : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase.
- chemical , immunology : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Recombinant Fusion Proteins.
- genetics : Influenza A Virus, H1N1 Subtype, Reassortant Viruses.
- growth & development : Influenza A Virus, H1N1 Subtype.
- immunology : Influenza A Virus, H1N1 Subtype.
- methods : Reverse Genetics.
- Amino Acid Sequence, Animals, Chlorocebus aethiops, Dogs, Humans, Madin Darby Canine Kidney Cells, Molecular Sequence Data, Sequence Alignment, Sequence Analysis, DNA, Vero Cells.

Abstract

The yield of influenza antigen production may significantly vary between vaccine strains; for example the A/California/07/09 (H1N1)-X179A vaccine virus, prepared during 2009 influenza pandemic, presented a low antigen yield in eggs compared to other seasonal H1N1 reassortants. In this study a bi-chimeric virus expressing HA and NA genes with A/Puerto Rico/8/34 (H1N1) (PR8) and X179A domains was rescued by reverse genetics using a mixture of Vero/CHOK1 cell lines (Medina et al. [7]). The bi-chimeric virus obtained demonstrated to yield much larger amounts of HA than X179A in eggs as measured by single-radial-immunodiffusion (SRID), the reference method to quantify HA protein in influenza vaccine. Such kind of optimized virus using PR8 backbone derived chimeric glycoproteins could be used as improved seed viruses for vaccine production.

DOI: 10.1016/j.vaccine.2015.06.112
PubMed: 26206270

Affiliations:

Links to Exploration step

pubmed:26206270

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.</title>
<author><name sortKey="Medina, Julie" sort="Medina, Julie" uniqKey="Medina J" first="Julie" last="Medina">Julie Medina</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boukhebza, Houda" sort="Boukhebza, Houda" uniqKey="Boukhebza H" first="Houda" last="Boukhebza">Houda Boukhebza</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: Houda.Boukhebza@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Saint Jean, Amelie" sort="De Saint Jean, Amelie" uniqKey="De Saint Jean A" first="Amélie" last="De Saint Jean">Amélie De Saint Jean</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: amelie.desaintjean@free.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: regis.sodoyer@bioaster.org.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: isabelle.legastelois@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: catherine.moste@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26206270</idno>
<idno type="pmid">26206270</idno>
<idno type="doi">10.1016/j.vaccine.2015.06.112</idno>
<idno type="wicri:Area/PubMed/Corpus">000628</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000628</idno>
<idno type="wicri:Area/PubMed/Curation">000628</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000628</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000602</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000602</idno>
<idno type="wicri:Area/Ncbi/Merge">001A58</idno>
<idno type="wicri:Area/Ncbi/Curation">001A58</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001A58</idno>
<idno type="wicri:Area/Main/Merge">000B29</idno>
<idno type="wicri:Area/Main/Curation">000B25</idno>
<idno type="wicri:Area/Main/Exploration">000B25</idno>
<idno type="wicri:Area/France/Extraction">000387</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.</title>
<author><name sortKey="Medina, Julie" sort="Medina, Julie" uniqKey="Medina J" first="Julie" last="Medina">Julie Medina</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boukhebza, Houda" sort="Boukhebza, Houda" uniqKey="Boukhebza H" first="Houda" last="Boukhebza">Houda Boukhebza</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: Houda.Boukhebza@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Saint Jean, Amelie" sort="De Saint Jean, Amelie" uniqKey="De Saint Jean A" first="Amélie" last="De Saint Jean">Amélie De Saint Jean</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: amelie.desaintjean@free.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: regis.sodoyer@bioaster.org.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: isabelle.legastelois@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: catherine.moste@sanofipasteur.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Marcy L'Etoile</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antigens, Viral (genetics)</term>
<term>Antigens, Viral (immunology)</term>
<term>Chlorocebus aethiops</term>
<term>Dogs</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (chemistry)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (growth & development)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (chemistry)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Molecular Sequence Data</term>
<term>Neuraminidase (genetics)</term>
<term>Reassortant Viruses (genetics)</term>
<term>Recombinant Fusion Proteins (chemistry)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Reverse Genetics (methods)</term>
<term>Sequence Alignment</term>
<term>Sequence Analysis, DNA</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Alignement de séquences</term>
<term>Analyse de séquence d'ADN</term>
<term>Animaux</term>
<term>Antigènes viraux (génétique)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Cellules Vero</term>
<term>Cellules rénales canines Madin-Darby</term>
<term>Chiens</term>
<term>Données de séquences moléculaires</term>
<term>Glycoprotéine hémagglutinine du virus influenza ()</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Génétique inverse ()</term>
<term>Humains</term>
<term>Protéines de fusion recombinantes ()</term>
<term>Protéines de fusion recombinantes (immunologie)</term>
<term>Sialidase (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (croissance et développement)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Séquence d'acides aminés</term>
<term>Vaccins antigrippaux ()</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virus recombinants (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Sialidase</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Protéines de fusion recombinantes</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Reverse Genetics</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Dogs</term>
<term>Humans</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Molecular Sequence Data</term>
<term>Sequence Alignment</term>
<term>Sequence Analysis, DNA</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Alignement de séquences</term>
<term>Analyse de séquence d'ADN</term>
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Cellules rénales canines Madin-Darby</term>
<term>Chiens</term>
<term>Données de séquences moléculaires</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Génétique inverse</term>
<term>Humains</term>
<term>Protéines de fusion recombinantes</term>
<term>Séquence d'acides aminés</term>
<term>Vaccins antigrippaux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The yield of influenza antigen production may significantly vary between vaccine strains; for example the A/California/07/09 (H1N1)-X179A vaccine virus, prepared during 2009 influenza pandemic, presented a low antigen yield in eggs compared to other seasonal H1N1 reassortants. In this study a bi-chimeric virus expressing HA and NA genes with A/Puerto Rico/8/34 (H1N1) (PR8) and X179A domains was rescued by reverse genetics using a mixture of Vero/CHOK1 cell lines (Medina et al. [7]). The bi-chimeric virus obtained demonstrated to yield much larger amounts of HA than X179A in eggs as measured by single-radial-immunodiffusion (SRID), the reference method to quantify HA protein in influenza vaccine. Such kind of optimized virus using PR8 backbone derived chimeric glycoproteins could be used as improved seed viruses for vaccine production. </div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Marcy L'Etoile</li>
</settlement>
</list>
<tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Medina, Julie" sort="Medina, Julie" uniqKey="Medina J" first="Julie" last="Medina">Julie Medina</name>
</region>
<name sortKey="Boukhebza, Houda" sort="Boukhebza, Houda" uniqKey="Boukhebza H" first="Houda" last="Boukhebza">Houda Boukhebza</name>
<name sortKey="De Saint Jean, Amelie" sort="De Saint Jean, Amelie" uniqKey="De Saint Jean A" first="Amélie" last="De Saint Jean">Amélie De Saint Jean</name>
<name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name>
<name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name>
<name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000387 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000387 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:26206270
   |texte=   Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:26206270" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

Serveur d'exploration sur les pandémies grippales

Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.

Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.